Table 1

Table of evidence of studies of AS

Study	Biological	Design	Duration	N	Q	LE	Age*	DD*	Women (%)	HLAB27+ (%)	Prior biologics (%)
Arends et al26	IFX, ETN, ADA	OP	24	220	0.91	2	42.9	15.0	31.0	81.0	0.0
Arends et al27	ETN	OP	48	92	0.75	2	41.2	9.0†	26.0	83.0	0.0
Braun et al28	IFX	RCT	12	34	0.65	3	40.6	16.4	32.0	91.0	0.0
Braun et al29	ADA	OP	12	1250	0.75	2	44.0	11.0	30.0	82.0	26.0
Davis et al30	ETN	RCT	24	138	0.83	3	42.1	10.1	24.0	84.0	0.0
de Vries et al31	IFX, ETN	OP	12	155	0.80	2	42.0	8.0†	35.0	79.0	0.0
Fagerli et al32	NA	OR	12	249	0.60	4	41.9	10.1	32.1	90.7	0.0
Fagerli et al33	NA	OR	12	289	0.61	4	42.4	9.9	32.6	90.5	0.0
FDA-103795/512325	ETN	RCT	24	138	0.65	3	42.1	10.0	24.0	84.0	NA
Glintborg et al34	IFX, ADA, ETN	OR	24	842	0.76	4	41.0†	5.0†	28.0	NA	0.0
Haibel et al35	ADA	RCT	52	46	0.65	3	37.4	7.5	54.3	67.3	2.1
Huang et al36	IFX	OP	10	63	0.76	2	32.8	10.9	20.0	90.5	0.0
Inman et al37	GOL	RCT	14	278	0.75	3	38.0	5.2†	28.1	83.0	0.0
Kim et al38	IFX	OP	22	23	0.60	2	41.4	8.7†	17.3	100.0	0.0
Kristensen et al39	IFX, ETN, ADA	OP	96	243	0.83	2	43.0	16.0	25.5	NA	0.0
Lord et al40	IFX, ETN, ADA	OP	24	261	0.91	2	43.0†	13.0†	18.0	NA	0.0
Luc et al41	IFX, ETN, ADA	OR	144	175	0.81	4	27.1	12.1	22.0	88.0	0.0
Maria Lizzio et al42	IFX	OP	54	47	0.51	2	46.8	14.7	NA	NA	NA
Morales-Lara et al43	IFX	OP	48	33	0.50	2	NA	NA	NA	NA	NA
Mulleman et al44	IFX	RCT	14	26	0.66	3	44.1†	4.2†	23.0	NA	15.3
Navarro-Compan et al45	NA	OP	12	20	0.55	2	42.4	6.8	14.0	83.3	NA
Ottaviani et al46	IFX	OR	24	155	0.83	4	43.1†	8.0†	36.7	64.9	NA
Pedersen et al47	IFX, ETN, ADA	OP	22	60	0.90	2	40.0†	12.0†	20.0	82.0	0.0
Perez-Guijo et al48	IFX	OP	30	19	0.60	3	37.4	14.2	NA	100.0	0.0
Ramiro et al49	NA	OR	12	197	0.75	4	NA	NA	NA	NA	NA
Rudwaleit et al52	IFX. ETN	RCT	12	99	0.78	3	38.4	14.8	32.0	89.0	0.0
Rudwaleit et al51	ADA	OP	12	1159	0.75	2	NA	NA	NA	NA	NA
Rudwaleit et al53	IFX, ETN	RCT	12	46	0.78	3	38.1	14.6	34.8	89.1	0.0
Rudwaleit et al50	ADA	OP	12	1250	0.75	2	44.0	11.0	30.0	82.0	26.0
Seitz et al54	IFX, ETN, ADA	OP	24	22	0.68	2	38.9	12.2	13.0	NA	NA
Sieper et al55	ADA	RCT	240	315	0.83	3	42.3	11.0	25.1	78.8	0.0
Stone et al56	IFX	OP	52	22	0.83	3	37.9†	8.7†	18.1	100.0	0.0
Tong et al57	IFX, ETN	OP	12	99	0.75	2	41.6	9.4	22.2	91.2	0,0
van der Heijde et al58	IFX	RCT	24	201	0.61	3	40.0	7.7	21.9	86.5	NA
van der Heijde et al1	ADA	RCT	24	208	0.61	3	41.7	11.3	24.5	78.4	0.0
Visvanathan et al59	IFX	RCT	24	201	0.80	3	40.0	10.1	21.9	86.5	0.0
Wagner et al60	GOL	RCT	14	76	0.83	3	39.8	NA	30.2	77.6	0.0

*Data are expressed in means (years).
†Data are expressed in medians.
ADA, adalimumab; DD, disease duration; ETN: etanercept; GOL, golimumab; IFX, infliximab; LE, level of evidence; N, number of patients; NA, not available; OP, observational prospective; OR, observational retrospective; Q, quality; RCT, randomised clinical trial.